Compare Adaptive Biotechnologies Corp (ADPT) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.51 (market cap $2.14B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AMC | |
|---|---|---|
Market Cap | $4.04B | $2.14B |
Sector | Health | Media |
52-Week High | $25.45 | $3.15 |
52-Week Low | $12.30 | $0.95 |
Enterprise Value | $4.10B | $9.08B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
AMC trades at $2.465, up 1.86% on the day, with a bullish technical signal and recent earnings beats. The company reported record revenue and EBITDA in Q2 2026, with improving cash flow trends. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion. Analyst consensus is mixed with a $3.00 price target.
Outlook hinges on sustained box office recovery and cost discipline to achieve profitability. Key risks include high debt load, competitive pressures, and reliance on blockbuster films. Upside potential exists if operational improvements continue, but financial stability remains a concern for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
